Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:TELO 21 November 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical data showing its lead drug Telomir-1 killed HL60 leukemia cells in vitro. Director Dr. Craig Eagle resigned from the board, effective November 14, with no dispute cited. TELO stock jumped 8% pre-market but recently traded at $1.39, down 3% from the prior close. Shares remain down about two-thirds year-to-date.
21 November 2025
··

Stock Market Today

  • WEX Inc. Shares Rise 3.43% on Strategic Partnerships and Strong Q4 Performance
    March 20, 2026, 5:32 PM EDT. WEX Inc. stock surged 3.43% amid renewed investor confidence driven by strategic partnership announcements and robust Q4 2025 results. The company posted an EBIT margin of 20.2% and EBITDA margin of 33%, highlighting solid operational efficiency and profitability. Despite a dip to $148.90, shares rebounded to $156.89. WEX's strong cash position of $1.68 billion and significant debt reduction of over $10.56 billion demonstrate financial stability. Analysts note the company's reasonable valuation, with a price-to-earnings ratio of 17.52 and manageable debt servicing ability. Technical indicators point to a support level near $150, suggesting potential upside if sector momentum continues. WEX's steady revenue growth and above-average returns reinforce its competitive stance in the finance sector.
Go toTop